Updated

Pharmaceutical developer ADARx filed for a U.S. initial public offering, targeting a $1.74 billion valuation as it seeks to capitalize on investor appetite for biotech firms with novel therapeutic approaches. The IPO would add to a growing pipeline of healthcare companies coming to market in 2026.